Becton Dickinson & Co. recalled 38 units of BD Veritor Connect Software on September 23, 2025. Unauthorized access to product service credentials may compromise data confidentiality and integrity. Users must stop using the software immediately and follow recall instructions.
Product service credentials used by some BD technical support teams to access certain BD products were accessed by an unauthorized actor. Until these product service credentials are updated, there is a risk of unauthorized access that may impact the confidentiality, integrity and/or availability of the relevant products and associated data.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Becton Dickinson & Co. or your healthcare provider for instructions. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
The recall involves BD Veritor Connect Software, Catalog Number 444881. This software transfers diagnostic results from the BD Veritor Plus Analyzer to BD Synapsys. The product was distributed worldwide, including the U.S. and several countries.
Unauthorized access to product service credentials poses a risk to the confidentiality, integrity, and availability of relevant products and data. This situation could lead to significant breaches in patient data security.
No specific incidents of injury or death have been reported. However, the potential for unauthorized access raises serious concerns regarding data privacy.
Stop using the BD Veritor Connect Software immediately. Contact Becton Dickinson & Co. or your healthcare provider for further instructions regarding the recall.
For more information, visit the Becton Dickinson recall page at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0240-2026. You can also reach their customer service for questions.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.